DIRECTORY
BIOTECH
Pharmaclient

Quick Click !

Monthly news

Home-Site

Contactexpress

Faqs

Legends

Home-Biotech

MEMORIES - POUR MÉMOIRE

Hereafter is a partial list of significant Biotech companies today disappeared or not any more legally French, to witness the memory of those entrepreneurs who took the risks for a risky venture : some were acquired (and a subsidiary may still be active in France), some were merged (and their name absorbed), some were liquidated... but most entrepreneurs started again
In a Biotech world that moves swiftly memory soon holds many holes... any data additions-contributions will be highly appreciated using the CONTACTEXPRESS form
Beware, obviously, website URL and e-mails may well be outdated
Pharmaclient : Mission, Keywords Biotech, Services... MORE?

Voici une liste partielle des entreprises Biotechs importantes, aujourd'hui disparues ou bien plus du tout Françaises (légalement), éditée pour rendre hommage aux entrepreneurs qui ont pris des risques pour un projet à risques : certaines ont été acquises (et une filiale peut encore être active en France), certaines ont été fusionnées (et leur nom a été absorbé), certaines ont été liquidées... mais la plupart des entrepreneurs ont recommencé
Dans un monde des Biotechs qui bouge très vite, la mémoire tôt se remplit de nombreux trous... toutes additions-contributions pour les données, en utilisant le formulaire de CONTACTEXPRESS seront vivement appréciées
Attention, évidemment, les URL et courriels sont probablement obsolètes
Pharmaclient : Mission, Mots-clés Biotech, Services... PLUS?

ONCE FRENCH BIOTECHS, TODAY ?... HATS-OFF TO VALOROUS TEAMS !

ADIATEC, ALPHELYS, APTANOMICS, BIONEXIS PHARMACEUTICALS, BIONISIS, CAREX, CELLPEP, CELLVIR, CELOGOS, CYTOMICS, DIATOS, DRUGABUSE SCIENCES, ECHOSENS, ENDOCELLS, GENODYSSEE, FOVEA PHARMACEUTICALS, GÉNOPOÏETIC, GENSET, HEMOSYSTEM, IDM PHARMA, IVAGEN, LIBRAGEN, MERISTEM THERAPEUTICS, MICROBIOCHIPS, MITOPROD, MUTABILIS, MYOSIX, NAUTILUS BIOTECH, NEURO3D, NEUROTECH, NOVEXEL, OPI, PRAXCELL, PROTÉUS, SHIGAMEDIX, SYNT:EM, THERAPTOSIS, TRANSAT, URRMA, VALIGEN, VIGICELL, ZETA BIOTECH

* ADIATEC *

1998 - Bretagne
Nantes
www.adiatec.fr

Design, Diagnostics
Key words: Immunoassay kits, Ophthalmology, Allergy, Eutest, Lacrytest, Mabtest, Amplitest
Mission: to develop and manufacture rapid assays for in vivo/in vitro diagnostics of ocular allergy, babies and children allergy, and for murine monoclonal antibodies isotyping
Clients: analysis labs, research labs
info@adiatec.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Lesser (Joël) [founder] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Brèche (Sébastien) Financers (Hist.): privately owned, business angels	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Ophthalmo Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2005 .12	Company liquidation	INFO	[7 years]
1998 .01	Company founded by Joël Lesser	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* ALPHELYS *

2001 - IDF
Plaisir
(near Paris)
www.alphelys.com

Design, Solutions
Key words: Instruments, Tissue array, Molecular histology, Imaging, Software, Reagents, Tisalys, Cresalys, MiniCore
Mission: to design, develop and market innovative integrated solutions including instruments, software and reagents for pathology and cytogenetics markets
Clients: Pharmaceutical industry, Research labs
info@alphelys.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Chaumat (Pierre) [co-founder, born 1965] Sc.Dir.-CSO: SalesMktg: Defrenaix (Pierre) [co-founder] Fin.Dir.-CFO: BusDev: Financers (Hist.): none (100% privately owned, capital 2007 = 0.04 M€, 2006 = 0.11 M€)	Turnover (M€) : 2.0 (2007) Total funding (M€) : 0.4 Last funding (M€) : n.a. Focus : Multiple Position : Preclin Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2011 .02	Company liquidation	INFO	[9 years]
2009 .12	Partnering distribution agreement with Biogen (USA) for Brazil market (exclusive distributor)	MKTG	[8 years]
2008 .05	Partnering distribution agreement with Zytomed Systems (Germany) for immunohistochemical reagents in France	MKTG	[6 years]
2006 .10	Partnering distribution agreement with Seroa (Monaco) for product portfolio in many countries worldwide	MKTG	[5 years]
2005 .06	Seed financing : 0.24 M€, by owners, as a capital increase from 0.16 M€ to 0.40 M€	SFIN	[3 years]
2002 .02	Company name change from Amelys to Alphelys, due to pre-occupied name	INFO	[0 year]
2001 .10	Company founded by Pierre Chaumat and Pierre Defrenaix (initially named Amelys)	ORGF	[0 year]

Actualisation / Updating: 3-May-2011

* APTANOMICS *

2001 - Rhône-Alpes
Lyon
www.aptanomics.com

Discovery, Drugs
Key words: Aptameres, Peptides, Cancer, Aptascreen, Aptaprint
Mission: to develop new treatments based on discovery of targets involved in signalling pathways that are deregulated in a broad range of cancers
Clients: Pharmaceutical industry (own development up to preclinical stage)
info@aptanomics.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Spin-off \| Managing Dir.-CEO: Chatelier (Jean) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): AGF P.E., CDC Ixis, Ventech, Biogestion	Turnover (M€) : 0.05 (2006) Total funding (M€) : 7.0 Last funding (M€) : 7.0 Focus : Cancers Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2007 .07	Financial complete burn-out and bankruptcy	INFO	[6 years]
2006 .11	Divestiture of some R&D assets to Imaxio (UK)	LICOUT	[5 years]
2005 .06	Partnering research agreement with Boehringer-Ingelheim in aptamer-based target validation	R&D	[4 years]
2003 .05	Nomination : Michael Courtney [ex-Transgene], as CEO	ORGN	[2 years]
2002 .11	1st round-financing : 7 M€, by AGF P.E., CDC Ixis, Ventech	RFINA	[1 year]
2001 .03	Company founded by John Hawken, Pierre Colas [Inserm, CSO], as a spin-off from Normale Sup (Lyon), based on patents from Massachusetts General Hospital	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* BIONEXIS PHARMACEUTICALS *

2002 - IDF
Paris
www.bionexis.com

Discovery, Drugs
Key words: Imaging radio-pharmaceuticals, Targeted drugs, Lipid-protein interaction, Apoptosis, Afim
Mission: to develop intelligent molecules for imaging and therapeutic applications, based on know-how on membrane protein-lipid interactions, focused on pathological apoptosis
Clients: Prescribers
info@bionexis.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Rodgers (Brid) [Ph.D. molecular biology, MBA, ex-Monitor] Sc.Dir.-CSO: Russo-Marie (Françoise) [co-founder, ex-Inserm] & Samson (Alain) [co-founder, University Professor] Fin.Dir.-CFO: BusDev: Financers (Hist.): Edmond de Rotschild I.P., Bioam, Sophia Euro lab, FCJE (CDC), CEA	Turnover (M€) : Total funding (M€) : 6.0 Last funding (M€) : 6.0 Focus : Cancers Position : Incubator Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2004 .12	Company liquidation	INFO	[2 years]
2004 .02	1st round-financing : 6 M€, led by Edmond de Rotschild I.P., with Bioam, Sophia Euro lab, FCJE (CDC), CEA	RFINA	[2 years]
2004 .02	Company move from Saclay (CEA) to Paris (Biotech)	RELOC	[2 years]
2002 .02	Company founded by Françoise Russo-Marie and Alain Samson	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* BIONISIS *

1999 - IDF
Le Plessis (near Paris)
www.bionisis.com

Contract, Research
Key words: High-throughput, Purification, OPLC technology (Optimum Performance Laminar Chromatography), Sorbent beds
Mission: to provide third parties with proprietary solutions for the separation, purification and analysis of chemical and biochemical mixtures resulting from organic synthesis, natural product extraction and biological fluids
Clients: Pharmaceutical industry, Research labs
webmaster@bionisis.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Manach (Michel) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Sofimac, Ventech, Siparex, OTC A.M.	Turnover (M€) : 0.5 (2004) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Subcontractor Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .03	Company liquidation	INFO	[8 years]
2002 .09	2nd round-financing : 2.5 M€	RFINB	[2 years]
1999 .10	Company founded by unknown entrepreneurs	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* CAREX *

2001 - Alsace
Strasbourg
www.carex.fr

Discovery, Drugs
Key words: Diabetes
Mission: to undertake innovative research of metabolic diseases, such as type 2 diabetes, obesity and dyslipidemia
Clients: Pharmaceutical industry
carex@carex.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Race (Geoffrey) [ex-Adprotech] Sc.Dir.-CSO: Fin.Dir.-CFO: Margetson (Shelley) BusDev: Financers (Hist.): Sofinnova Partners, GIMV, Mara Ventures (USA), Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM	Turnover (M€) : Total funding (M€) : 31.0 Last funding (M€) : 25.0 Focus : Metabolism Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .05	Acquisition by 7TM Pharma (Denmark)	ACQ-	[5 years]
2004 .03	2nd round-financing : 25 M€, by Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM, and previous shareholders	RFINB	[3 years]
2002 .07	Nomination : Geoffrey Race, as CEO		[1 year]
2002 .04	1st round-financing : 6 M€, led by Sofinnova Partners, GIMV and Mara Ventures	RFINA	[1 year]
2001 .11	Company founded by Johan Auwerx, Pierre Chambon, Samir S. Deeb, Hana Koutnikova, Jürgen M.Lehmann, based on research from Institut de Génétique et de Biologie Moléculaire et Cellulaire, by Pierre Chambon (President of the board)	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* CELLPEP *

1998 - IDF
Paris
www.cellpep.fr

Delivery, Drugs
Key words: Generics, Value-added, Long acting release, Formulation, Octreotide, Goserelin
Mission: to develop therapeutics in oncology and infectious diseases
Clients: Pharmaceutical industry
jpboulan@cellpep.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: de Rougé (Bonabes) [co-founder, M.D., ex-Servier, Beaufour-Ipsen] Sc.Dir.-CSO: Mollard (Michel) [co-founder, also Seventure, ex-Beaufour-Ipsen, Cooper] Fin.Dir.-CFO: BusDev: Financers (Hist.): Seventure	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .03	Acquisition by Procyon (Canada), for 39 MUS$, to form a new legal entity, Ambrilia Biopharma (www.ambrilia.com)	ACQ-	[8 years]
2003 .03	Round-financing : 3.8 M€, by Turenne Capital Partenaires, OTC Asset Management, H2i Management, Synergènes	RFIN	[5 years]
1998 .00	Company founded by Bonabes de Rougé, Michel Mollard and others	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* CELLVIR *

2006 - IDF
Évry
(near Paris)
www.cellvir.com

Discovery, Drugs
Key words: Anti-retrovirals, AIDS, HCV, SARS, Avian Flu
Mission: to develop a new generation of anti-retrovirals by targeting the host-virus protein-protein interactions
Clients: Pharmaceutical industry (own clinical development up to phase IIa)
michael.courtney@cellvir.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Courtney (Michael) [Scottish, Ph.D., ex-Aptanomics, Noxxon, Trangene (CSO)]
Sc.Dir.-CSO: Benarous (Richard) [co-founder, born 1941, M.D., Ph.D., ex-Hybrigenics (co-founder), Cytomics (co-founder)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): OSEO, ANRS, ANR, Genopole 1er Jour and INSERM Transfert
Note (February 2010) : the company website is unavailable and the URL does not exist any more (temporarily ?)
Note (October 2010) : the company is announced (unconfirmed) as a 100% subsidiary of Mutabilis, itself a subsidiary of Pharma Omnium International, a private equity fund

Turnover (M€) : n.a.
Total funding (M€) : 2.0
Last funding (M€) : 2.0
Focus : Virus
Position : Incub
Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2010 .11	Company struck off	LEGAL	[4 years]
2008 .06	Seed financing : 2 M€, by Genopole 1er Jour and Inserm Transfert Initiative	SFIN	[2 years]
2006 .08	Patent : granted from Inserm (spin-off)	LEGAL	[0 year]
2006 .03	Company founded by Richard Benarous, Richard Platford, Armand Frydman, E.Thomas Bader, Jean Deregnaucourt	ORGF	[0 year]

Actualisation / Updating: 5-Apr-2011

* CELOGOS *

2001 - IDF
Paris
www.celogos.fr

Discovery, Drugs
Key words: Muscle regeneration, Cell repair, Technology platform, Rational Cell Design (RCD), Stress urinary incontinence, Anal incontinence, Ocular myopathies
Mission: to develop and produce innovative cell-based technologies in the field of cellular medicine
Clients: Pharmaceutical industry
contact@celogos.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Ulmann (André) [M.D., Ph.D. endocrinology, ex-Hoechst, Roussel Uclaf] Sc.Dir.-CSO: Pinset (Christian) [founder, M.D., ex-CNRS, Institut Pasteur] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned	Turnover (M€) : Total funding (M€) : 3.0 Last funding (M€) : n.a. Focus : Muscle Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .01	Acquisition by HRA Pharma of majority share, with Celogos maintained as a French subsidiary and Christian Pinset as CSO	ACQ-	[4 years]
2005 .11	Partnering research agreement, HRA Pharma, for pharmaceutical development process of future lead compounds	R&D	[4 years]
2001 .08	Company founded by Christian Pinset, cell therapy expert and Didier Montarras (from Institut Pasteur, in Paris)	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* CYTOMICS *

2000 - IDF
Orsay
(near Paris)
www.cytomics.fr

Discovery, Drugs
Key words: Ubiquitin ligases, UbiScreen, High-throughput Screening, Cancer, Nosocomial Fungal Infections
Mission: to discover and develop small molecules controlling protein turnover, to treat serious human diseases, notably inflammatory diseases and cancer and nosocomial fungal infections
Clients: Prescribers
info@cytomics.fr

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Cambou (Bernard) [born 1955, MBA (Essec), ex-StageMark (co-founder), Aventis-Principia, HGS, MIT]
Sc.Dir.-CSO: Hercend (Thierry) [born 1952, oncologist, also Supervisory Board President, Cytomics, BT Pharma]
Fin.Dir.-CFO: Martin (Erwan) [Sup de Co (Toulouse), MBA, ex-Syndex]
BusDev:
Financers (Hist.): Société Générale A.M., Edmond de Rotschild I.P., Truffle Venture

Turnover (M€) : none (2008)
Total funding (M€) : 13.0
Last funding (M€) : 10.0
Focus : Cancers
Position : Preclin
Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .12	Company liquidation	INFO	[10 years]
2008 .03	Company move to Orsay (from nearby Gif-sur-Yvette) and rename as Cytomics Pharmaceuticals (from Cytomics Systems)	ORGL	[7 years]
2007 .10	Financing (no interest loan) : 2.1 M€, by OSEO, to support its ongoing program in the anti-fungal area (second Oseo grant)	DEBT	[7 years]
2007 .03	Nomination : Bernard Cambou, new CEO, Prof. Dominique Thomas, founder, resigns	ORGN	[6 years]
2006 .02	2nd round-financing : 10.0 M€, by Edmond de Rotschild I.P., Truffle Venture and previous shareholders	RFINB	[5 years]
2003 .02	1st round-financing : 3.0 M€, by Société Générale A.M., and others	RFINA	[2 years]
2000 .04	Company founded by Dominique Thomas, at initially, Gif-sur-Yvette (near Paris), in collaboration with Richard Benarous (initially as Cytomics Systems, then from February 2008, as Cytomics Pharmaceuticals)	ORGF	[0 year]

Actualisation / Updating: 5-Apr-2011

* DIATOS *

1999 - IDF
Paris
www.diatos.com

Delivery, Drugs
Key words: Drug delivery, Peptides, Tumor targeting, Cancer, Chemotherapy, Prodrugs, Liposome, Vectocell, DaunoXome
Mission: to research, develop and market targeted anti-cancer drugs based on drug-delivery improvements
Clients: Prescribers
contact@diatos.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Tchélingérian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder)]
Sc.Dir.-CSO: Gasmi (Jamal) [M.D. Oncology, Ms. Sciences, ex-Roche, Gustave Roussy]
Fin.Dir.-CFO:
SalesMktg: Cowburn (James) [Ph.D. Biochemistry, ex-Zeneus Pharma, Roche, Schering Plough]
BusDev:
Financers (Hist.): GIMV, InterWest Partners, Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners, NIF, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), Innoven, BFF, Credit Agricole P.E.

Turnover (M€) : 0.49 (2007), 0.30 (2006)
Total funding (M€) : 54.8
Last funding (M€) : 9.4
Focus : Cancers
Position : Trade
Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2009 .05	Company bankruptcy (in need of € 10 Million re-financing), then liquidation	INFO	[10 years]
2008 .12	Licensing-out of DTS-108, a pro-drug of irinotecan to Drais (with co-development)	LICOUT	[9 years]
2008 .08	Clinical trial (phase IIa) for DTS-201, a peptidic prodrug of doxorubicin (beginning)	CLIN	[9 years]
2007 .07	4th round-financing : 9.4 M€, by Credit Agricole P.E. and previous shareholders	RFIND	[8 years]
2006 .07	Listing : failure of IPO introduction on Alternext, cancelled due to unfavorable market conditions	PBO	[7 years]
2006 .05	Licensing-in of specialty cancer product from Gilead	LICIN	[7 years]
2005 .04	Set-up of US subsidiary in California, USA (Business)	ORGC	[6 years]
2004 .03	Set-up of subsidiary in Leuven, Belgium (R&D)	ORGC	[5 years]
2004 .02	3rd round-financing : 7.0 M€, by Innoven and BFF (Biotech Fund Flanders)	RFINC	[5 years]
2003 .05	2nd round-financing : 9.0 M€, by NIF and Crédit Lyonnais P.E. (today Crédit Agricole P.E.)	RFINB	[4 years]
2003 .04	Licensing-out of cancer improved-delivery drug development to Medarex	LICOUT	[4 years]
2000 .10	1st round-financing : 15.5 M€, led by GIMV and InterWest Partners, with Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners	RFINA	[1 year]
1999 .05	Seed financing : 1.5 M€, by Sofinnova Partners (subsequently John Tchélingérian joins the company as business developper)	SFIN	[0 year]
1999 .02	Company founded by Prof. Stratis Avraméas, Dr Thérèse Ternynck, as a spin-off from Institut Pasteur	ORGF	[0 year]

Actualisation / Updating: 18-May-2009

* DRUGABUSE SCIENCES *

1997 - Rhône-Alpes
Villeurbanne
(near Lyon)
www.drugabusesciences.com

Discovery, Drugs
(also, Delivery, Drugs)
Key words: Antagonism, Addiction, Alcoholism, Toxicomany, Cocaine, Opioids, Naltrexone Depot
Mission: to discover, develop and market medications for the treatment of alcohol and substance abuse and dependence
Clients: Prescribers
mdupire@drugabusesciences.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Langlois (Patrick) [born 1945, ex-Aventis (Board member, Rhône Poulenc]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): CDC Ixis, Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management
Note : company initially founded in USA (Hayward, California) in December 1994, with an additional base in Paris in December 1997, then legally moved to France in 2004 (through a reversed merger)

Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Addiction
Position : Clinical
Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .05	Company liquidation : legal dissolution	INFO	[10 years]
2007 .01	Divestiture of assets (product portfolio, including naltrexone) to Elbion (Belgium) for undisclosed terms	ACQ-	[9 years]
2006 .06	Listing on Alternext processed : 20 M€ expected (failed)	PBO	[8 years]
2004 .01	Acquisition of mother US company by French subsidiary, with new CEO (Robert Floch) and 4.0 M€ convertible loan by CDC Ixis	ACQ+	[6 years]
2001 .04	Round-financing : 27.0 M€, by Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management	RFIN	[3 years]
1999 .10	Round-financing : 21.0 M€, by 3i, ABN Amro, Auriga, CDC Innovation, Financière de Brienne, Nomura, Parnib, Partech, Rothschild Asset Management, Société Générale A.M.	RFIN	[1 year]
1997 .12	Company founded by Philippe Pouletty (today Truffle Ventures), with name also shortened as DAS	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* ECHOSENS *

2001 - IDF
Paris
www.echosens.com

Discovery, Devices
Key words: Obesity, Hepatitis C, Hepatitis B, Fibroscan
Mission: to develop, manufacture and market new diagnostic devices in the field of hepatology (FibroScan being the first and only non-invasive device for diagnosis and monitoring of hepatic fibrosis)
Clients: Hospitals (through distributors and subsidiaries)
communication@echosens.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Guillaume (Richard) [born 1955, ex-Blatchford, Abbott, Mead Johnson] Sc.Dir.-CSO: Sandrin (Laurent) [co-founder, ESCPI, Ph.D. physics, ex-LOA] Fin.Dir.-CFO: BusDev: Financers (Hist.): OTC Asset Management, Cap Décisif	Turnover (M€) : 8.1 (2008), 7.2 (2007) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Liver Position : Clinical Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2011 .03	Acquisition by Inner Mongolia Free Han & Mongolia Pharmaceuticals (China), for undisclosed sum	ACQ-	[9 years]
2008 .12	Nomination : Richard Guillaume, new CEO, replacing Bertrand Fourquet	ORGN	[7 years]
2007 .00	Set-up of 3 subsidiaries in Spain, Germany and China, more than 330 FibroScan® installed worldwide	ORGC	[5 years]
2004 .00	Round-financing : undisclosed M€, by OTC and Cap Décisif, beginning of the commercialization of FibroScan with dedicated probe in France	RFIN	[2 years]
2003 .11	CE mark obtained for FibroScan	MKTG	[2 years]
2001 .06	Company founded by Sylvain Yon [born 1974], Bertrand Fourquet [Essec, as CEO], Laurent Sandrin, Jean-Michel Hasquenoph [ESTP], supported by ANVAR	ORGF	[0 year]

Actualisation / Updating: 4-Apr-2011

* ENDOCELLS *

2004 - IDF
Paris
www.no-website.net

Design, Therapy
Key words: Cell therapy, Transplantation, Type 1 Diabetis, Insulin
Mission: to generating lines of human pancreatic beta cells immortalized in culture for transplantation therapies
Clients: Research labs
dslagel@esperanteventures.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Slagel (Dean) [born 1970] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Diabetes Position : Incub Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .05	Acquisition by Esperante Ventures (Holland)	ACQ-	[3 years]
2004 .08	Company founded by Prof. Paul Czernichow [M.D. pediatry], Raphaël Scharfmann [Inserm]	ORGF	[0 year]

Actualisation / Updating: 24-Sep-2008

* FOVEA PHARMACEUTICALS *

2005 - IDF
Paris
www.fovea-pharma.com

Discovery, Drugs
Key words: Ophthalmology, Allergy conjunctivitis, Mavular edema, Retinitis pigmentosa
Mission: to discover and develop new treatments focused on ocular diseases (dry eye, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy), with a special focus on retinal pathologies
Clients: Pharmaceutical industry (own development, up to preclinical)
info@fovea-pharma.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Gilly (Bernard) [born 1957, Ph.D. bioeconomy, ex-Sofinnova, Transgene (CEO), Pasteur-Mérieux-Connaught]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Davitian (Bernard) [born 1960, MBA, ex-Neurotech (CEO), Transgene, Pasteur-Mérieux]
Oper.Dir.: Bélichard (Pierre) [ex-Urogene, Ethypharm, Fournier]
BusDev: Sternberg (Garry) [M.D., MBA, ex-Eyetech, BMS]
Financers (Hist.): Sofinnova Partners, CAPE, Abingsworth Mangement, The Wellcome Trust, GIMV

Turnover (M€) : 0.04 (2007), 0.005 (2006)
Total funding (M€) : 50.5
Last funding (M€) : 30.0
Focus : Ophthalmo
Position : Preclin
Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2009 .10	Acquisition by Sanofi Aventis (France), for 370 M€ (maximum, depending on milestones)	ACQ-	[4 years]
2009 .05	Clinical trial (proof-of-concept, positive) for Prednisporin (FOV1101) in patients with persistent allergic conjunctivitis	CLIN	[4 years]
2009 .02	Licensing-in of European rights of an ocular formulation of DX-88 for the treatment of retinal diseases from Dyax	LICIN	[3 years]
2007 .12	2nd round-financing : 30.0 M€, by previous shareholders	RFINB	[2 years]
2007 .11	Partnering research agreement with Genzyme	R&D	[2 years]
2005 .11	1st round-financing : 20.5 M€, by Sofinnova Partners, CAPE, Abingsworth Management, The Wellcome Trust, GIMV	RFINA	[0 year]
2005 .05	Company founded by Bernard Gilly, Pierre Bélichard, Prof. José-Alain Sahel (professor, Ophthalmology), based on platform from INSERM research unit 592	ORGF	[0 year]

Actualisation / Updating: 5-Oct-2009

* GENODYSSEE *

1999 - IDF
Évry
(near Paris)
www.genodyssee.com

Discovery, Drugs
Key words: Protein optimization, Low-burn model, Interferon, HCV
Mission: to discover superior protein products by using a unique, IP-protected approach and a proprietary genomic DNA databank
Clients: Prescribers
escary@genodyssee.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Escary (Jean-Louis) [founder, born 1964, Ph.D. molecular biology, ex-UCLA, CNG, ] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Matignon I.F., Edmond de Rotschild Fin., Société Générale A.M., George Cohen	Turnover (M€) : 0.11 (2007), 0.17 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Virus Position : Preclin Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .10	Company liquidation	INFO	[11 years]
2008 .02	Patent : notice of Allowance of US Application for lead compound (Interferon alpha variant 17)	LEGAL	[8 years]
2006 .10	Partnering research agreement with Baxter on therapeutic proteines derived from natural genetiques variations	R&D	[7 years]
2000 .05	1st round-financing : 8.1 M€, led by Matignon I.F., with Edmond de Rotschild Fin., Société Générale A.M., George Cohen	RFINA	[0 year]
1999 .10	Company founded by Jean-Louis Escary (the first company incubated at Evry Genopole)	ORGF	[0 year]

Actualisation / Updating: 5-Apr-2011

* GÉNOPOÏETIC *

1993 - Rhône-Alpes
Miribel (Ain)
www.genopoietic.fr

Discovery, Drugs
Key words: Autologous vaccine
Mission: to develop autologous chondrocytes for cartilage repair, gene therapy to treat cancer, as well as to treat graft-versus-host disease (innovative anticancer drugs)
Clients: Pharmaceutical industry
info@genopoietic.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Star-up \| Managing Dir.-CEO: Fourthin (Isabelle) [M.D., MBA Essec, ex-MSD, Osteotech] Sc.Dir.-CSO: Fourthin (Isabelle) Fin.Dir.-CFO: BusDev: Financers (Hist.): Rhône-Poulenc Rorer (Gencells), then Avax (listed on US Stock Exchange)	Turnover (M€) : n.a. Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Cancers Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .11	Nomination : François R. Martelet (Avax CEO since 2007) as President, and Isabelle Fourthin as Managing Director	ORGN	[14 years]
2000 .08	Acquisition by Avax Technologies, Philadelphia (USA)	ACQ-	[6 years]
1994 .11	Round-financing : undisclosed M€, by Rhône-Poulenc Rorer (France), against a minority share to support gene therapy trials	RFIN	[0 year]
1993 .12	Company founded by David Klatzmann and Jean-Loup Salzmann with the support of UPMC (Université Pierre et Marie Curie), with Charles Salzmann as CEO	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* GENSET *

1989 - IDF
Paris
www.genset.fr

Discovery, Drugs
Key words: Pharmacogenomics, DNA sequences
Mission: to undertake research programs in the field of genomics, to analyze the regulatory sequences of the human genome and to initiate the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases, notably for CNS and metabolism
Clients: Pharmaceutical industry, Research labs
contacts@genset.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Pernet (André) Sc.Dir.-CSO: Vassuer (Marc) [co-founder, Ph.D.] Pharm.Dir.: Ravel (Denis) [Ph.D.] Fin.Dir.-CFO: BusDev: Financers (Hist.): J.P. Morgan, Public Note : in 1999, Genset reported identifiable assets of 80.9 Million € and had subsidiaries in USA, Japan, Singapore, and Australia	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Incub Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2002 .06	Acquisition by Serono (Switzerland) [today Merck-Serono]	ACQ-	[13 years]
1996 .06	Listing on Nasdaq : 100 MUS$ (about 80 M€)	PBO	[7 years]
1989 .00	Company founded by Marc Vasseur (a leading French scientist), Pascal Brandys (CEO, venture capitalist)	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* HEMOSYSTEM *

1999 - Méditerranée
Marseille
www.hemosystem.com

Discovery, Diagnostics
Key words: Bacteria, Micro-array, ScanSystem
Mission: to develop new diagnostic tools and associated devices to improve safety in blodd transfusion medecine
Clients: Blood transfusion centers, Hospitals
info@hemosystem.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Hermet (Jean-Pierre) [founder, MBA, ex-Bentley Pharma, American Home Products, Allergan] Sc.Dir.-CSO: Besson-Faure (Isabelle) [Pharm.D., ex-Stago] Fin.Dir.-CFO: Allione (Monique) [Sup de Co (Marseille), DESCF, ex-Quater Oats, Irex (Synthelabo)] BusDev: Financers (Hist.): Société Générale A. M., XAnge, Avenir Finance Gestion, FJCE (CDC)	Turnover (M€) : 0.7 (2004) Total funding (M€) : 5.3 Last funding (M€) : 3.0 Focus : Hematology Position : Trade Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .10	Company liquidation	INFO	[7 years]
2004 .09	Round-financing : 3.0 M€, by FCJE (CDC), and previous shareholders	RFIN	[5 years]
1999 .05	Company founded by Jean-Pierre Hermet (CEO)	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* IDM PHARMA *

1987 - IDF
Paris
www.idm-biotech.com

Discovery, Drugs
Key words: Melanoma, Sarcoma, Infectious diseases, Junovan
Mission: to develop innovative products that activate the immune system to treat cancers
Clients: Prescribers
idm@idm-biotech.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Romet-Lemonne (Jean-Loup) [co-founder] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Cancers Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2009 .05	Acquisition by Takeda, for US$ 75 Million	ACQ-	[22 years]
2008 .02	Partnering research agreement ended with Sanofi-Aventis, after disappointing results on Junovan	R&D	[21 years]
2007 .06	Nomination : Timothy Walbert, new CEO and Chairman, with resignation by founder Jean-Loup Romet-Lemonne	ORGN	[20 years]
2005 .03	Acquisition by Epimune, as a merger with name change from IDM to IDM-Pharma	ACQ-	[18 years]
2002 .12	Round-financing : 20.0 M€, by Sanofi-Synthelabo (exclusive, shareholding : 11%)	RFIN	[15 years]
2002 .01	Partnering research agreement with Sanofi-Synthelabo	R&D	[15 years]
2000 .11	Round-financing: 48.9 M€	RFIN	[13 years]
1993 .12	Company founded by Jean-Loup Romet-Lemonne (as Immuno-Designed Molecules, IDM)	ORGF	[6 years]

Actualisation / Updating: 5-Jun-2009

* IVAGEN *

2002 - Méditerranée
Bernis
(near Nîmes)
www.ivagen.com

Discovery, Diagnostics
Key words: Immuno-hematology, Medical devices, HIV, H5N1
Mission: to develop, manufacture and distribute reagents to assist third parties in human, veterinary and plant diagnosis, and to discover proprietary immuno-diagnostics
Clients: Research labs
contact@ivagen.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Skorski (Gilbert) [born 1955] Sc.Dir.-CSO: Da Costa (Jean-Manuel) Fin.Dir.-CFO: BusDev: Financers (Hist.): Matignon I.G., OTC Asset Management (33%) Communication: website under construction, since long	Turnover (M€) : 1.05 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Virus Position : Trade Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .07	Company liquidation	INFO	[6 years]
2007 .04	Round-financing : undisclosed M€, by Matignon I.G., OTC Asset Management (after receivership in 2004)	RFIN	[5 years]
2002 .02	Company founded by Jean-Claude Aziza (unexpectedly deceased in 2006), Gilbert Skorski	ORGF	[0 year]

Actualisation / Updating: 31-Oct-2008

* LIBRAGEN *

2001 - Midi-Pyrénées
Toulouse
www.libragen.com

Design, Manufacturing
(also, Contract, Research)
Key words: Bioprocesses, Enzymes, Bio-catalysis, Meta-Dna libraries, Small molecules identification, Micro-organisms, Auriose
Mission: to discover, develop and improve innovative bioprocesses for the industrial production of healthcare molecules, by building on bacterial diversity, based on cooperation with 4 Public research units (Inra, Insa, Lyon CNRS, Orsay CNRS)
Clients: Pharmaceutical industry, Chemical industry, Cosmetics industry, Food industry
contact@libragen.com

Age: . AGE() . year(s)

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Nalin (Renaud) [born 1967, Ph.D., ex-CRO] Sc.Dir.-CSO: Lefèvre (Fabrice) [Ph.D., Insa, ex-Protéus] Tech-Dev: Auriol (Daniel) [Ph.D. biochemical engineering, ex-CRITT, Solabia] Fin.Dir.-CFO: BusDev: Financers (Hist.): Bioam, Galia Gestion, CDC Entreprises, Irdi, Socri	Turnover (M€) : 0.69 (2009), 0.31 (2008), 0.18 (2007) Total funding (M€) : 3.0 Last funding (M€) : 2.2 Focus : Studies Position : Proof-of-Concept Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .12	Acquisition by Induchem (Switzerland)	ACQ-	[9 years]
2010 .04	Launch of NovHyal, a new cosmetic formulation in S3D regenerative serum	MKTG	[9 years]
2010 .01	Sustainable process intensification in the manufacturing of its cosmetic actives, Inoveol	MKTG	[8 years]
2008 .12	Launch of Inoveol (www.inoveol.com) actives (stable polyphenol cosmetic compounds) on the US market	MKTG	[7 years]
2008 .09	Partnering research agreement with DSM, to co-develop transaminases for production of chiral amines	R&D	[7 years]
2006 .01	Partnering research agreement with Pierre Fabre, enzymatic synthesis	R&D	[4 years]
2005 .11	Partnering research agreement with Minakem on biocatalysis and organic synthesis (green chemistry, fine chemicals)	R&D	[4 years]
2005 .06	Nomination : Fabrice Lefèvre, as CSO	ORGN	[4 years]
2004 .09	Company move from Lyon to Toulouse	ORGL	[3 years]
2004 .05	1st round-financing : 2.2 M€, by BIOAM, Galia Gestion, and IRDI (Midi Pyrénées V.C.)	RFINA	[3 years]
2001 .03	Seed financing : 0.75 M€, by Bioam	SFIN	[0 year]
2001 .02	Company founded by Renaud Nalin and Pascal Simonet [CNRS] in Lyon	ORGF	[0 year]

Actualisation / Updating: 9-May-2011

* MICROBIOCHIPS *

2006 - IDF
Paris
www.microbiochips.com

Design, Diagnostics
Key words: Biochip, Micro-arrays, Cytokine, Anti-body, MicroVigene
Mission: to speed up third parties research with customized designed micro-arrays and to exclusively distribute in Europe micro-arrays from other biotech companies (also to develop own micro-arrays, as nano-arrays, in partnership with Toulouse CNRS)
Clients: Pharmaceutical industry, Agro industry, Cosmetics industry
after-sales-services@microbiochips.com

Age: . AGE() . year(s)

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Saulot (Vincent) [co-founder, born 1975, Ph.D., Eng. Insa, ex-BioMedical Diagnostic, Chiron] Sc.Dir.-CSO: Malingue (Frédéric) [ex-Biorad] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)	Turnover (M€) : 0.21 (209), 0.25 (2008), 0.23 (2007), none (2006) Total funding (M€) : 0.3 Last funding (M€) : 0.3 Focus : Multiple Position : Trade Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .09	Acquisition by BioSystems International (by partial transfer of assets of MBC to BSI) with company struck off on August 17. 2011	ACQ-	[4 years]
2010 .02	Licensing-in of PlasmaScan antibody microarray products that speed-up identification of human plasma biomarkers from Biosystems	LICIN	[3 years]
2009 .01	Partnering marketing agreement (worldwide) with Abcam on custom antibody arrays	MKTG	[2 years]
2008 .08	Company move from Evreux to Paris with 10 times more space	ORGL	[2 years]
2008 .07	Set-up of UK subsidiary in London (led by Pascal Azabian)	ORGC	[2 years]
2008 .06	Certification : ISO 9001-2000	INFO	[2 years]
2007 .02	Partnering distribution agreement with Vigene Tech, for the US market	MKTG	[0 year]
2006 .05	Company founded by Dr Vincent Saulot and Pascal Azabian, based in Evreux incubator	ORGF	[0 year]

Actualisation / Updating: 28-Sep-2011

* MERISTEM THERAPEUTICS *

1998 - Centre
Clermont-Ferrand
www.meristem-therapeutics.com

Design, Drugs
(also Discovery, Drugs)
Key words: Therapeutic Proteins, Gene technology, Plants, MABs, Manufacturing, Processing, Third Parties, Merispase, Cystic fibrosis
Mission: to produce therapeutic proteins (e.g., monoclonal antibodies) for third parties needs, with many advantages in comparison to other systems (biological safety, high flexibility, low cost), and to develop own portfolio of innovative therapeutic proteins
Clients: Pharmaceutical industry, Biotechs
meristem@meristem-therapeutics.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Rohmer (Jean-Paul) [born 1947, Ph.D. Management, Dauphine, ex-Eli Lilly, Stallergènes (CEO)]
Sc.Dir.-CSO: Burtin (Daniel) [Ph.D. Biochemistry, ex-INRA]
Oper.Dir.: Boisgard (Catherine) [ex-Human Resources]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Limagrain (Unigrains), BNP, Tethys, 3i, Sofipar, Sofimac, AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF

Turnover (M€) : 0.17 (2006)
Total funding (M€) : 60.0
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .08	Company liquidation	INFO	[10 years]
2007 .10	Court : applications on appeal for GMO corn testing, rejected by tribunal	LEGAL	[9 years]
2004 .02	Nomination : Jean-Paul Rohmer, chairman of Supervisory Board	ORGN	[5 years]
2002 .06	4th round-financing : 21.5 M€, by AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF, and previous shareholders	RFIND	[4 years]
2001 .07	Listing : failure of IPO introduction due to unfavorable financial environment for 54 M€ expected	PBO	[3 years]
2000 .11	Acquisition of Sedaherb, phyto-subcontractor to pharmaceutical industry, for around 1 year turnover, 3.5 M€	ACQ+	[2 years]
2000 .06	3rd round-financing : 10.0 M€, by BNP, Tethys, 3i, Sofipar, Sofimac	RFINC	[2 years]
1999 .02	2nd round-financing : 18.3 M€, by Banexi Ventures 2, Banexi, 3i, Sofimac (Société de Financement du Massif Central), Sofipar (groupe Crédit Agricole) and capital disposal by Limagrain to the financial investors	RFINB	[0 year]
1998 .05	1st round-financing : 10.0 M€, by Limagrain	RFINA	[0 year]
1998 .04	Company founded by Limagrain (Agro-food cooperative company, the number one seed producer in Europe), based on an innovative technology (Molecular Pharming) developped since 1992	ORGF	[0 year]

Actualisation / Updating: 16-Feb-2009

* MITOPROD *

2004 - Aquitaine
Bordeaux
www.mitoprod.com

Contract, Manufacturing
Key words: RNA-factory, Mitochondrial DNA, Yeast, Custom nucleotides, RNA Genix
Mission: to use proprietary technology of RNA production based on its own exclusive license in order to produce most promising molecules for third parties
Clients: Pharmaceutical industry
contact@mitoprod.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Plane (Guillaume) [born 1978, co-founder, Ms. biochemistry (Bordeaux)] Sc.Dir.-CSO: Fin.Dir.-CFO: Perrin (Patrick) [Ms. economy, ex-Flamel Technology, Ernst&Young] Techn.Dir.-CTO: Schaal (Oriane) [Ph.D., ex-Covalab] BusDev: Amandine (Jacques) Financers (Hist.): Aquitaine Création Innovation, Business angels, privately owned	Turnover (M€) : 0.059 (2007) Total funding (M€) : 2.2 Last funding (M€) : 1.6 Focus : Multiple Position : Trade Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2011 .03	Company liquidation	INFO	[6 years]
2009 .03	Partnering distribution agreement with Sigma-Aldrich for Customized Long RNA Oligonucleotides	MKTG	[4 years]
2009 .01	Patent : granted on new class of interfering RNA, called ciRNA (circularization of the active molecules)	LEGAL	[4 years]
2008 .02	Partnering distribution agreement with Eurobio Labs for European market	MKTG	[3 years]
2006 .05	1st round-financing : 1.6 M€, by undisclosed investors	RFINA	[1 year]
2005 .05	Seed financing : 0.14 M€, by Aquitaine Création Innovation	SFIN	[0 year]
2004 .09	Company founded by Guillaume Plane (CEO), Nathalie Bonnefoy [CNRS], based on a technology discovered by Dr. Jean-Paul di Rago [CNRS, also co-founder]	ORGF	[0 year]

Actualisation / Updating: 3-May-2011

* MUTABILIS *

2001 - IDF
Romainville
(near Paris)
www.mutabilis.fr

Discovery, Drugs
Key words: Antibacterials, Severe infections, Nosocomial diseases
Mission: to identify and develop new antibacterial therapies in the fields of vaccines, antibodies and classic antibiotics
Clients: Prescribers
partners@mutabilis.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Stéphane Huguet [born 1955, President P.O.I., ex-Pharmacia, Phoenix, Fournier, Sandoz]
Sc.Dir.-CSO: Escaich (Sonia) [Ph.D., ex-Sandoz, Rhône Poulenc]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Bioam, AXA P.E., Inserm-Transfert, Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.)
Note : website revamped in May 2008, URL changed from «.com» to «.fr» in December 2009 with a single page and mention of company owned by Pharma Omnium International (a private equity fund) which also announces to own CellVir in October 2010, URL vanished in 2011

Turnover (M€) : 0.13 (2008), 0.12 (2006)
Total funding (M€) : 10.2
Last funding (M€) : 8.0
Focus : Infections
Position : Clinical
Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .06	Company struck off	LEGAL	[8 years]
2009 .06	Acquisition by start-up Pharma Omnium International (France), with company name maintained and Stéphane Huguet (Président POI), back as CEO	ACQ-	[7 years]
2007 .10	Nomination : Stephan Fischer as CEO	ORGN	[6 years]
2005 .04	Partnering research agreement with Chiron (today Novartis) to develop new generation of prophylactic vaccines	R&D	[3 years]
2004 .06	2nd round-financing : 8.0 M€, by Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), and previous shareholders	RFINB	[2 years]
2002 .07	1st round-financing : 2.0 M€, by Bioam, AXA P.E., Inserm-Transfert	RFINA	[0 year]
2002 .03	Nomination : Stéphane Huguet [ex-Pharmacia, Phoenix, Fournier, Sandoz] as CEO	ORGN	[0 year]
2001 .08	Company founded by Prof. Xavier Nassif, as a spin-off from Inserm	ORGF	[0 year]

Actualisation / Updating: 5-Apr-2011

* MYOSIX *

2000 - IDF
Paris
www.myosix.com

Discovery, Immunology
Key words: Cell Transplantation, Muscle cells, Myopathies, Saint-Louis, Genzyme
Mission: to develop cell-based therapies for diseases with unmet medical needs, such as myopathies, based on expertise in muscle cell technology
Clients: Hospitals
contact@myosix.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Academic \| Managing Dir.-CEO: Deleuze (Christian) [Genzyme, Med.Dr, ESSEC 1994, ex-Daiichi-Sankyo, Pharmacia, Searle, Bayer, Pasteur-Mérieux-Connaught] Sc.Dir.-CSO: Dalle (Bruno) [Pharm.D.] Fin.Dir.-CFO: BusDev: Ritsou (Elena) Financers (Hist.): privately owned (51%), Genzyme (49%)	Turnover (M€) : 0.05 (2008), 0.06 (2007), 0.03 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Muscle Position : Clinical Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2011 .02	Company liquidation	INFO	[10 years]
2010 .09	Nomination : Christian Deleuze as CEO	ORGN	[10 years]
2010 .02	Patent : granted in EU, for MX' technology, on new class of interfering RNA, called ciRNA (circularization of the active molecules)	LEGAL	[9 years]
2008 .09	Certification : cell therapy laboratory as an authorized center to prepare Cell Therapy Product of clinical use, by AFSSAPS	INFO	[8 years]
2008 .04	Partnering manufacturing agreement with Association Française contre les Myopathies (AFM, i.e. French Muscular Dystrophy Association) to support research on muscular pathologies and cell therapy	INDUS	[7 years]
2007 .04	Production : cell therapy (beginning) in Saint Louis hospital (Paris)	INDUS	[6 years]
2002 .11	Clinical trial (phase II) for cell therapy (beginning, first worldwide)	CLIN	[2 years]
2002 .07	Partnering research agreement with Genzyme, including capital sharing (49%)	R&D	[1 year]
2000 .09	Company founded by Dr Jean-Thomas Vilquin, Prof. Jean-Pierre Marolleau and Dr Scorsin, from a patent application on myoblast production technology filed by AP-HP, AFM (French Muscular Dystrophy Association) and INSERM	ORGF	[0 year]

Actualisation / Updating: 9-May-2011

* NAUTILUS BIOTECH *

2000 - IDF
Évry
(near Paris)
www.nautilusbiotech.com

Delivery, Drugs
Key words: Therapeutic Proteins, Slow-released HGH, Interferon alpha, Vitatropin, Belerofon
Mission: to develop therapeutic proteins with novel and superior pharmacological profiles compared with established best-in-class protein drugs
Clients: Prescribers
contact@nautilusbiotech.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Parkinson (Philip) [born 1956, MBA, ex-Pfizer France] Sc.Dir.-CSO: Drittanti (Lila) [ex-Genethon] Fin.Dir.-CFO: BusDev: Vega (Manuel) [co-founder, born 1960, Ph.D., ex-Microgen, Genethon] Financers (Hist.): Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.	Turnover (M€) : 0.38 (2006) Total funding (M€) : 25.3 Last funding (M€) : 8.4 Focus : Multiple Position : Prereg Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .11	Company liquidation	INFO	[8 years]
2007 .04	Clinical trial (phase I) for Belerofon in USA (beginning)	CLIN	[7 years]
2007 .04	4th round-financing : 8.4 M€, by Pre-IPO Invest, Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.	RFIND	[7 years]
2007 .02	Partnering research agreement with Wyeth on hemophilia therapies	R&D	[7 years]
2005 .02	3rd round-financing : 7.25 M€, by Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.	RFINC	[5 years]
2005 .02	Nomination : Philip Parkinson as CFO (then CEO, in 2007)	ORGN	[5 years]
2003 .10	Nomination : Reinhard Koenig [M.D.], as Vice President Clinical & Regulatory Affairs of Nautilus Biotech USA	ORGN	[3 years]
2000 .08	1st round-financing : 0.9 M€, by undisclosed investors	RFINA	[0 year]
2000 .01	Company founded by Dr Manuel Vega (CEO) et Paul Martin	ORGF	[0 year]

Actualisation / Updating: 11-Jan-2009

* NEURO3D *

2000 - Alsace
Mulhouse
www.neuro3d.com

Discovery, Drugs
(also, Contract, Research)
Key words: CNS, Psychiatry, Schizophrenia, Ocaperidone
Mission: to develop innovative treatments for psychiatric disorders such as schizophrenia, depression or anxiety
Clients: Prescribers
contact@neuro3d.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Woler (Charles) Sc.Dir.-CSO: Fin.Dir.-CFO: Coste (Julien) BusDev: Financers (Hist.): Sofinnova Partners, Apax Partners	Turnover (M€) : 1.0 (2004) Total funding (M€) : 70.0 Last funding (M€) : 31.5 Focus : Multiple Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2007 .03	Liquidation and divestiture of R&D assets to Evotec (Germany)	INFO	[6 years]
2005 .05	Clinical trial (phase III) for key lead compound, ocaperidone, licensed to J&J (beginning)	CLIN	[4 years]
2004 .12	4th round-financing : 31.5 M€, by previous shareholders	RFIND	[4 years]
2003 .09	3rd round-financing : 10.0 M€, by previous shareholders	RFINC	[3 years]
2003 .05	Acquisition of Neurofit (France), a biotech CRO	ACQ+	[2 years]
2002 .09	2nd round-financing : 20.0 M€, led by HealthCap, with Techno Venture Management and previous shareholders	RFINB	[2 years]
2002 .03	Licensing-out of Ocaperidone to Janssen (J&J)	LICOUT	[1 year]
2000 .11	1st round-financing : 7.6 M€, by founder V.C., Apax Partners	RFINA	[0 year]
2000 .09	Company founded by Sofinnova, Charles Woler (CEO), Jean-Jacques Bourguignon, Jean-Paul Macher	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* NEUROTECH *

1998 -
www.neurotech.fr

Discovery, Drugs
Key words: Retinatis, CNTF, Encapsulated Cell Technology
Mission: to develop sight-saving therapeutics for chronic retinal diseases
Clients: Prescribers
t.shepherd@neurotech.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Shepherd (Tom) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Ophthalmo Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .06	Company move from Paris to Delaware (USA), as the legal domicile, with change in nationality and website as www.neurotechusa.com	ORGL	[8 years]
2003 .11	4th round-financing : 12.0 M€, led by Apax Partners and Merlin Biosciences, with previous shareholders (3i Plc, GIMV, West LB, Atlas Venture and Ergo Equity)	RFIND	[5 years]
2002 .01	Licensing-in agreement of CNTF with Amgen in all ophthalmology indications	LICIN	[4 years]
2001 .05	3rd round-financing : 35.0 M€, led by Apax Partners and Merlin Biosciences with Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, AGF Innovation, and previous shareholders (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, IMH)	RFINC	[3 years]
2000 .00	Set-up of US subsidiary in Lincoln	ORGC	[1 year]
1998 .10	Company founded by unknown entrepreneurs	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* NOVEXEL *

2004 - IDF
Romainville
(near Paris)
www.novexel.com

Discovery, Drugs
Key words: Anti-infectives, Anti-fungals
Mission: to develop novel antibacterials designed to overcome the significant global problem of bacterial resistance
Clients: Prescribers
info@novexel.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Buchanan (Iain) [born 1952, ex-Vertex, J&J, Biogen]
Sc.Dir.-CSO: Coleman (Kenneth) [Ph.D. microbiology, ex-AstraZeneca, SmithKline Beecham]
Fin.Dir.-CFO: Waldron (Gordon) [B.A. political science, ex-Syntem, Texas Instruments, Spie Batignolles]
BusDev: Mangasarian (Aram) [Ph.D. biology, MBA, ex-ExonHit Therapeutics]
Financers (Hist.): Sanofi-Aventis, Atlas Venture, Sofinnova, 3i, Abingworth, Novo

Turnover (M€) : 8.5 (2008)
Total funding (M€) : 90.0
Last funding (M€) : 50.0
Focus : Infections
Position : Clinical
Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2010 .03	Company move from Romainville to USA (premises down, 40 staffs out)	ORGL	[5 years]
2009 .12	Acquisition by AstraZeneca (UK) for at least US$ 430 Millions	ACQ-	[5 years]
2008 .11	Clinical trial (phase II) for combined NXL104/ceftazidime in Hospital Patients with complicated Urinary Tract Infections (beginning)	CLIN	[4 years]
2008 .04	Licensing-out of NXL 104, a beta-lactamase inhibitor, to Forest (USA), with € 75 Millions upfront payment	LICOUT	[3 years]
2008 .01	Set-up of US subsidiary in Pennsylvania	ORGC	[3 years]
2007 .01	2nd round-financing : 50.0 M€, led by Edmond de Rothschild I.P., with Goldman Sachs, NeoMed, NIF SMBC, and previous shareholders	RFINB	[2 years]
2006 .12	Licensing-in of Aminocandin from Indevus Biotech (USA)	LICIN	[2 years]
2005 .10	Clinical trial (phase I) for NXL 103 (beginning)	CLIN	[1 year]
2004 .12	1st round-financing : 40.0 M€, led by Atlas Venture, with Sofinnova, 3i, Abingworth, Novo	RFINA	[0 year]
2004 .12	Company founded by Dominique Le Beller and others, as a spin-off from Sanofi-Aventis [ex-Aventis Pharma]	ORGF	[0 year]

Actualisation / Updating: 16-Mar-2010

* OPI *

1999 - Rhône-Alpes
Lyon
www.orphan-opi.com

Discovery, Drugs
Key words: Orphan diseases, Hematology, Cancer, Transplants, Kidrolase, Erwinase
Mission: to discover and develop new treatment for orphan diseases
Clients: Pharmaceutical industry
opi@orphan-opi.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Alberici (Gilles) [founder, Pharm.D., Ph.D. immunotoxicology, ex-Mérieux, IMTIX-Sangstat] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): founder, Biomérieux, Sofimac, CDC-PME, Innoveris, SPEF, Siparex	Turnover (M€) : Total funding (M€) : 13.0 Last funding (M€) : 6.4 Focus : Multiple Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2007 .03	Acquisition by Eusa Pharma (USA)	ACQ-	[8 years]
2004 .04	3rd round-financing : 6.4 M€, led by SPEF and Siparex, with previous shareholders	RFINC	[5 years]
2003 .05	Acquisition of Diaclone (France)	ACQ+	[4 years]
2003 .00	2nd round-financing : 4.5 M€, by Sofimac, CDC-PME, Innoveris	RFINB	[3 years]
2001 .00	1st round-financing : 1.1 M€, by previous shareholders	RFINA	[1 year]
1999 .01	Company founded by Gilles Alberici [ex-Imtix, CEO], as 'Orphan Pharma International'	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* PRAXCELL *

2003 - Midi-Pyrénées
Ramonville Saint-Agne
(near Toulouse)
www.praxcell.com

Contract, Services
Key words: Medical devices, Cellular therapy, Stem cells, Cord blood, Kits, Hematopoietic, Endothelial
Mission: to supply human stem cells isolated from cord blood, human Umbilical Vein Endothelial Cells (HUVEC) and human Mesenchymal Stem Cells (MSC) prepared from the umbilical cord for the utilisation of stem cells in the medical, pharmaceutical, cosmetic and biotechnical researches
Clients: Research labs
commercial@praxcell.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Eymeri (Michel) [co-founder, born 1954] Sc.Dir.-CSO: Richard (Patrice) [co-founder, M.D.], Zeng (Lin) [co-founder, , born 1954, M.D.] Oper.Dir.-COO: Prévots (Fabien) [born 1960] Fin.Dir.-CFO: BusDev: Financers (Hist.): Galia Gestion, Fonds d'Amorçage Midi-Pyrénées, privately owned	Turnover (M€) : 0.05 (2009), 0.03 (2008), 0.11 (2007) Total funding (M€) : 1.2 Last funding (M€) : 0.5 Focus : Multiple Position : Clinical Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .10	Company liquidation	INFO	[6 years]
2007 .11	Round-financing : 1.5 M€, in preparation	RFIN	[4 years]
2006 .10	Seed financing : 0.5 M€, by Galia Gestion and Fonds d'Amorçage Midi Pyrénées	SFIN	[2 years]
2003 .11	Company founded by Dr Patrice Richard, Dr Lin Zeng, Michel Eymeri	ORGF	[0 year]

Actualisation / Updating: 28-Dec-2010

* PROTÉUS *

1998 - Méditerranée
Nîmes
www.proteus.fr

Design, Drugs
Key words: Proteins, Engineering, Manufacturing, Immunoline
Mission: to discover, engineer, optimize and manufacture new proteins and protein-based products and processes for third parties and own research
Clients: Pharmaceutical industry, Chemical industry (Degussa, Henkel, Aventis/Adisseo, Thales, Veolia Environment)
info@proteus.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Ravot (Gilles) [born 1970, Ph.D. microbiology, Eng. ESIL, ex-Sanofi-Recherche] Sc.Dir.-CSO: Ravot (Gilles) Fin.Dir.-CFO: Vander Linden (Marc) BusDev: Bloch (Jean-François) [also deputy CEO, co-founder, born 1961, Pharm.D., ex-Oris, CEA] Financers (Hist.): PCAS (32%) Notes : fully distinct from US-based biotech company Proteus Biomedical	Turnover (M€) : 2.07 (2008), 1.6 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Trade Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2010 .09	Acquisition by PCAS (100%), after minority share in 2007	ACQ-	[12 years]
2007 .10	Round-financing : undisclosed M€, as a share capital increase reserved for industrial partner PCAS, from 6% to 32%	RFIN	[9 years]
2005 .07	Set-up of PSI, new division to trade protein services and production	ORGC	[7 years]
1999 .09	Seed financing : 0.2 M€, by Axa P.I., Natexis Ventech	SFIN	[1 year]
1998 .01	Company founded by Daniel Dupret (CEO, then President up to 2007) [co-founder, born 1956, Eng. Insa, ex-Transgene, Appligene], Jean-François Bloch, Jean-Marie Sonet [PCAS] and others	ORGF	[0 year]

Actualisation / Updating: 13-Dec-2010

* SHIGAMEDIX *

2005 - IDF
Paris
www.shigamedix.com

Discovery, Immunology
Key words: Antigen vectorization, Vaccines, Cancer, Infectious diseases, STxB Platform
Mission: to develop new vaccines based on antigen vectorization STxB proprietary technology designed to specifically target the dendritic cells
Clients: Prescribers
info@shigamedix.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Spin-off \| Managing Dir.-CEO: Zacharie (Jean-Marie) [born 1941, HEC, Insead (MBA), ex-MSD] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)	Turnover (M€) : 0.036 (2007), 0.13 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Vaccines Position : Preclin Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2009 .06	Company liquidation	INFO	[3 years]
2007 .11	Partnering research agreement with GSK Biologicals on vaccines	R&D	[2 years]
2006 .10	Nomination : Jean-Marie Zacharie, as President and CEO	ORGN	[1 year]
2005 .08	Company founded by Ludger Johannes [Ph.D.] from Curie Institute/CNRS and Eric Tartour [M.D./Ph.D.]	ORGF	[0 year]

Actualisation / Updating: 31-Oct-2008

* SYNT:EM *

1995 - Méditerranée
Nîmes
www.syntem.com

Discovery, Drugs
(also, Delivery, Drugs)
Key words: CNS, Brain barrier
Mission: to develop new drugs as well as to deliver compounds to the brain or other intracellular targets, based on proprietary Pep:trans and Acti:map technology platforms, in the field of CNS diseases
Clients: Prescribers
syntem@syntem.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Kaczorek (Michel) Sc.Dir.-CSO: Fin.Dir.-CFO: Waldron (Gordon) BusDev: Financers (Hist.): Apax Partners, Banexi Ventures, 3i, BankInvest, Lombart-Odier	Turnover (M€) : Total funding (M€) : 32.0 Last funding (M€) : n.a. Focus : CNS Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .01	Acquisition by CLL Pharma (France), a development stage drug delivery pharmaceutical company, in shares	ACQ-	[11 years]
2004 .11	Acquisition (failed) by Sonus (USA), for 30 MUS$ in shares	ACQ-	[9 years]
1995 .00	Company founded by Michel Kaczorek (CEO), Caroline Roussel	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* THERAPTOSIS *

2001 - IDF
Romainville
(near Paris)
www.theraptosis.com

Discovery, Drugs
Key words: Apoptosis control, Cancer, Neuro-degenerative diseases, CytoTrust, MitoTrust
Mission: to design and develop drugs acting on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases
Clients: Pharmaceutical industry (own development up to clinical trials)
info@theraptosis.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Spin-off \| Managing Dir.-CEO: Chesnoy (Olivier) [born 1958, M.D., ex-Fournier] Sc.Dir.-CSO: Jacotot (Etienne) [Ph.D., ex-Theraptosis (CEO)] Fin.Dir.-CFO: Boussard (Jean-François) [Ph.D.] BusDev: Financers (Hist.): Auriga Partners, EdRIP, SPEF, CDC, Blue Medical, Anvar	Turnover (M€) : 0.07 (2006) Total funding (M€) : 16.7 Last funding (M€) : 8.4 Focus : Cancers Position : Preclin Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .12	Company liquidation (board of directors based decision)	INFO	[7 years]
2007 .09	Nomination : Olivier Chesnoy [M.D.] as CEO	ORGN	[6 years]
2007 .02	Company move to the Biocitech Park at Romainville (Paris North)	ORGL	[5 years]
2006 .12	2nd round-financing : 8.4 M€, led by Auriga Partners, with Blue Medical, Seventure, Edmond de Rothschild (EdRIP), CDC entreprises (FCJE)	RFINB	[5 years]
2006 .10	Registration : orphan drug designation by EMEA for a treatment of neonatal brain damage	MKTG	[5 years]
2002 .07	1st round-financing : 2.5 M€, by undisclosed investors	RFINA	[1 year]
2001 .03	Company founded by Léna Edelman and Etienne Jacotot, as a spin-off from Institut Pasteur, Paris	ORGF	[0 year]

Actualisation / Updating: 13-Nov-2009

* TRANSAT *

2002 - Rhône-Alpes
Saint-Priest
(near Lyon)
www.biotransat.com

Design, Drugs
(also Contract, Research)
Key words: Target delivery, Viral vectors, Functional genomics, Plasmid developments, Cellular models, Molecule libraries, RNA interference
Mission: to provide taylored cellular models and gene expression studies in functional genomics for third parties
Clients: Pharmaceutical industry, Biotech, Academic labs
transat@transatbiotechnology.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Chappuis (Sophie) [Ph.D., EM Lyon, ex-CNRS] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Evolem, Oseo, Région Rhône-Alpes, privately owned	Turnover (M€) : 0.5 (2006) Total funding (M€) : 1.2 Last funding (M€) : 1.2 Focus : Genome Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .03	Company liquidation	INFO	[5 years]
2006 .01	Seed financing : 1.2 M€, by Evolem, Oseo, Région Rhône-Alpes, and Philippe Desmarescaux (born 1938), as business angel	SFIN	[3 years]
2002 .12	Company founded by Sophie Chappuis and Marc Billaud (CNRS)	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* URRMA *

2001 - Méditerranée
Aubagne
(near Marseille)
www.urrma.eu

Discovery, Drugs
(also, Discovery, Diagnostics)
Key words: Antiretroviral, HIV, B-lymphocytes, R7V technology
Mission: to develop and bring to market innovative products in treatment and pronostic of HIV infected patients based on Professor Jean-Claude Chermann's knowledge of HIV disease
Clients: Prescribers
contact@urrma.eu

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Chermann (Jean-Claude) [born 1939, M.D., co-discoverer of AIDS virus, Professor, ex-Institut Pasteur, Inserm] Sc.Dir.-CSO: Chermann (Jean-Claude) and Camille Haslin [Ph.D. sciences, ex-CNRS] Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : 1.75 (2008), 4.3 (2007) Total funding (M€) : 15.0 Last funding (M€) : 9.0 Focus : Virus Position : Preclin Company confirm : none

History

* VALIGEN *

1996 - IDF
Courbevoie (near Paris)
www.valigen.com

Discovery, Drugs
Key words: Genomics, Chimeraplasty
Mission: to research in therapeutic target identification and validation using the tools of functional genomics and gene expression analysis, for treatments of cardio-vascular and metabolic conditions, and some cancers
Clients: Pharmaceutical industry, Agro industry
webmaster@valigen.com

DATE	MILESTONE	TYPE	TIME
2010 .06	Company liquidation, with legal suite from Jean-Claude Chermann to minority shareholders	INFO	[9 years]
2008 .03	3rd round-financing : 9.0 M€, by undisclosed investors	RFINC	[6 years]
2005 .11	Round-financing : undisclosed M€, by private investors	RFIN	[4 years]
2001 .06	Company founded by Prof. Jean-Claude Chermann, Camille Haslin and Urrma Biopharma, based in Montreal, as a J.V. with a French subsidiary, which has since August 2004 become a French independent legal entity	ORGF	[0 year]

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Tharaud (Cécile) [Polytechnique, Ph.D., MBA, ex-Glaxo, SB] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : 0.18 (2001) Total funding (M€) : 30.0 Last funding (M€) : n.a. Focus : Multiple Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2002 .05	Company liquidation	INFO	[5 years]
2001 .05	Nomination : Cécile Tharaud, as CEO	ORGN	[4 years]
2000 .02	Acquisition of Kimeragen (USA), by merger	ACQ+	[3 years]
1997 .02	Acquisition of Infogen (Germany)	ACQ+	[0 year]
1996 .12	Company founded by Jean-Louis Pourny, from the merger of Valigène (France) and Kimeragen (USA)	ORGF	[0 year]

Actualisation / Updating: 12-May-2008

* VIGICELL *

1999 - IDF
Villejuif
(near Paris)
www.vigicell.eu

Contract, Services
Key words: Predictive toxicology, Genotoxicity, Toxichip, Angiogenesis
Mission: to provide third parties with services designing, performing and interpreting predictive toxicology tests, based on proprietary in-house developed tools
Clients: Research labs
vigicell@vigicell.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Gilbert (Jean-Emmanuel) [born 1967, Ph.D.] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned, with a minority share by SucSeed (a specialist biotech & IT seed fund) and Addes	Turnover (M€) : 0.23 (2009), 0.25 (2008), 0.2 (2006) Total funding (M€) : n.a. Last funding (M€) : 0.5 Focus : Studies Position : Subcontractor Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2010 .09	Company liquidation	INFO	[11 years]
2008 .11	Seed financing : 0.5 M€, by business angels and private investors (undisclosed)	SFIN	[9 years]
2007 .06	Partnering research agreement with L'Oréal	R&D	[8 years]
2002 .05	Nomination : Jean-Emmanuel Gilbert [Ph.D.], as CEO	ORGN	[2 years]
1999 .06	Company founded by Yolène Thomas [Ph.D., CNRS], Jean-Paul Oudinet [Ph.D., CNRS], Isaac Béhar [Ph.D.] and others	ORGF	[0 year]

Actualisation / Updating: 9-May-2011

* ZETA BIOTECH *

2005 - Bretagne
Lannion
www.zetabiotech.com

Development, Diagnostics
Key words: Electrophoresis, Molecular gel, UltraPag
Mission: to develop and market a new generation of electrophoresis supports (UltraPag gel is the first deshydrated electrophoresis support worldwide)
Clients: Research labs, Pharmaceutical industry, Chemical industry
zetabiotech@zetabiotech.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Guyader (Antony) [co-founder, born 1976, M.Sc. biochemistry] Sc.Dir.-CSO: Fin.Dir.-CFO: Viola (Bruno) [co-founder, Sup de Co Brest, ex-Corvis, Alcatel, Pirelli/Cisco] BusDev: Financers (Hist.): privately-owned (founders, 60%), private investors, public	Turnover (M€) : 0.011 (2007) Total funding (M€) : n.a. Last funding (M€) : 1.5 Focus : Testing Position : Trade Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2010 .04	Company liquidation	INFO	[4 years]
2008 .07	Production : set-up of full manufacturing line	INDUS	[2 years]
2007 .06	Listing on Euronext Paris : 1.5 M€	PBO	[1 year]
2005 .10	Company founded by Antony Guyader and Bruno Viola	ORGF	[0 year]

Actualisation / Updating: 29-Jan-2011

Actualisation 29 Septembre 2011 / Updating 29 September 2011

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT

Pour retourner à la page d'accueil Biotech: BIENVENUE ! Haut de page :

DIRECTORYBIOTECHPharmaclient

MEMORIES - POUR MÉMOIRE

ONCE FRENCH BIOTECHS, TODAY ?... HATS-OFF TO VALOROUS TEAMS !

* ADIATEC *

Identity

History

* ALPHELYS *

Identity

History

* APTANOMICS *

Identity

History

* BIONEXIS PHARMACEUTICALS *

Identity

History

* BIONISIS *

Identity

History

* CAREX *

Identity

History

* CELLPEP *

Identity

History

* CELLVIR *

Identity

History

* CELOGOS *

Identity

History

* CYTOMICS *

Identity

History

* DIATOS *

Identity

History

* DRUGABUSE SCIENCES *

Identity

History

* ECHOSENS *

Identity

History

* ENDOCELLS *

Identity

History

* FOVEA PHARMACEUTICALS *

Identity

History

* GENODYSSEE *

Identity

History

* GÉNOPOÏETIC *

Identity

History

* GENSET *

Identity

History

* HEMOSYSTEM *

Identity

History

* IDM PHARMA *

Identity

History

* IVAGEN *

Identity

History

* LIBRAGEN *

Identity

History

* MICROBIOCHIPS *

Identity

History

* MERISTEM THERAPEUTICS *

Identity

History

* MITOPROD *

Identity

History

* MUTABILIS *

Identity

DIRECTORY
BIOTECH
Pharmaclient